PURPOSE: Because of the large and continuous energetic requirements of brain function, neurometabolic dysfunction is a key pathophysiologic aspect of the epileptic brain. Additionally, neurometabolic dysfunction has many self-propagating features that are typical of epileptogenic processes, that is, where each occurrence makes the likelihood of further mitochondrial and energetic injury more probable. Thus abnormal neurometabolism may be not only a chronic accompaniment of the epileptic brain, but also a direct contributor to epileptogenesis. METHODS: We examine the evidence for neurometabolic dysfunction in epilepsy, integrating human studies of metabolic imaging, electrophysiology, microdialysis, as well as intracranial EEG and neuropathology. RESULTS: As an approach of noninvasive functional imaging, quantitative magnetic resonance spectroscopic imaging (MRSI) measured abnormalities of mitochondrial and energetic dysfunction (via 1H or 31P spectroscopy) are related to several pathophysiologic indices of epileptic dysfunction. With patients undergoing hippocampal resection, intraoperative 13C-glucose turnover studies show a profound decrease in neurotransmitter (glutamate-glutamine) cycling relative to oxidation in the sclerotic hippocampus. Increased extracellular glutamate (which has long been associated with increased seizure likelihood) is significantly linked with declining energetics as measured by 31P MR, as well as with increased EEG measures of Teager energy, further arguing for a direct role of glutamate with hyperexcitability. DISCUSSION: Given the important contribution that metabolic performance makes toward excitability in brain, it is not surprising that numerous aspects of mitochondrial and energetic state link significantly with electrophysiologic and microdialysis measures in human epilepsy. This may be of particular relevance with the self-propagating nature of mitochondrial injury, but may also help define the conditions for which interventions may be developed.
PURPOSE: Because of the large and continuous energetic requirements of brain function, neurometabolic dysfunction is a key pathophysiologic aspect of the epileptic brain. Additionally, neurometabolic dysfunction has many self-propagating features that are typical of epileptogenic processes, that is, where each occurrence makes the likelihood of further mitochondrial and energetic injury more probable. Thus abnormal neurometabolism may be not only a chronic accompaniment of the epileptic brain, but also a direct contributor to epileptogenesis. METHODS: We examine the evidence for neurometabolic dysfunction in epilepsy, integrating human studies of metabolic imaging, electrophysiology, microdialysis, as well as intracranial EEG and neuropathology. RESULTS: As an approach of noninvasive functional imaging, quantitative magnetic resonance spectroscopic imaging (MRSI) measured abnormalities of mitochondrial and energetic dysfunction (via 1H or 31P spectroscopy) are related to several pathophysiologic indices of epileptic dysfunction. With patients undergoing hippocampal resection, intraoperative 13C-glucose turnover studies show a profound decrease in neurotransmitter (glutamate-glutamine) cycling relative to oxidation in the sclerotic hippocampus. Increased extracellular glutamate (which has long been associated with increased seizure likelihood) is significantly linked with declining energetics as measured by 31P MR, as well as with increased EEG measures of Teager energy, further arguing for a direct role of glutamate with hyperexcitability. DISCUSSION: Given the important contribution that metabolic performance makes toward excitability in brain, it is not surprising that numerous aspects of mitochondrial and energetic state link significantly with electrophysiologic and microdialysis measures in humanepilepsy. This may be of particular relevance with the self-propagating nature of mitochondrial injury, but may also help define the conditions for which interventions may be developed.
Authors: W Serles; L M Li; S B Antel; F Cendes; J Gotman; A Olivier; F Andermann; F Dubeau; D L Arnold Journal: Epilepsia Date: 2001-02 Impact factor: 5.864
Authors: Alexei P Kudin; Tatiana A Kudina; Jan Seyfried; Stefan Vielhaber; Heinz Beck; Christian E Elger; Wolfram S Kunz Journal: Eur J Neurosci Date: 2002-04 Impact factor: 3.386
Authors: Ibrahim Elias Nasseh; Débora Amado; Esper A Cavalheiro; Maria da Graça Naffah-Mazzacoratti; Célia Harumi Tengan Journal: Epilepsy Res Date: 2005-12-07 Impact factor: 3.045
Authors: David Araújo; Antônio C Santos; Tonicarlo R Velasco; Lauro Wichert-Ana; Vera C Terra-Bustamante; Veriano Alexandre; Carlos G Carlotti; João A Assirati; Hélio Rubens Machado; Roger Walz; João P Leite; Américo C Sakamoto Journal: Epilepsia Date: 2006-08 Impact factor: 5.864
Authors: H P Hetherington; R I Kuzniecky; K Vives; O Devinsky; S Pacia; D Luciano; B Vasquez; S Haut; D D Spencer; J W Pan Journal: Neurology Date: 2007-12-11 Impact factor: 9.910
Authors: Douglas L Rothman; Henk M De Feyter; Robin A de Graaf; Graeme F Mason; Kevin L Behar Journal: NMR Biomed Date: 2011-08-31 Impact factor: 4.044
Authors: Sarmad Siddiqui; Stephen Kadlecek; Mehrdad Pourfathi; Yi Xin; William Mannherz; Hooman Hamedani; Nicholas Drachman; Kai Ruppert; Justin Clapp; Rahim Rizi Journal: Adv Drug Deliv Rev Date: 2016-09-04 Impact factor: 15.470
Authors: Kathryn Adamiak Davis; Ravi Prakash Reddy Nanga; Sandhitsu Das; Stephanie H Chen; Peter N Hadar; John R Pollard; Timothy H Lucas; Russell T Shinohara; Brian Litt; Hari Hariharan; Mark A Elliott; John A Detre; Ravinder Reddy Journal: Sci Transl Med Date: 2015-10-14 Impact factor: 17.956